Highest reported pathologic complete response rate seen in a phase 3 registrational trial for HER2 positive early breast cancer with favorable safety profile versus standard treatment DESTINY-Breast11 ...
Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Non–Small-Cell Lung Cancer Twenty-nine patients with newly diagnosed LARC ...
Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199 Margin positivity after rectal ...
Daiichi Sankyo and AstraZeneca’s ENHERTU followed by THP showed an improved safety profile versus standard of care First phase 3 trial to demonstrate benefit of ENHERTU in early breast cancer Results ...
Neoadjuvant talazoparib conferred pathologic complete response rates comparable with those of anthracycline- and taxane-based chemotherapy regimens among patients with germline BRCA1/BRCA2-mutated, ...
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)-- Positive results from the DESTINY-Breast11 phase 3 trial showed ENHERTU ® (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab ...
Highest reported pathologic complete response rate seen in a Phase III registrational trial for HER2-positive early breast cancer with favorable safety profile vs. standard treatment DESTINY-Breast11 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback